Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSC2499550A · 1 trial · 1 indication
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
| Arm | Type | Description |
|---|---|---|
| Treatment A: MSC2499550A | EXPERIMENTAL | MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition |
| Treatment B: Cysticide | EXPERIMENTAL | Cysticide® 40 mg/kg under fed condition |
| Treatment C: MSC2499550A | EXPERIMENTAL | C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition |
| Treatment D: MSC2499550A | EXPERIMENTAL | MSC2499550A 20 mg/kg under fasting condition |
| Treatment E: MSC2499550A | EXPERIMENTAL | MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition |
| Name | Type | Description |
|---|---|---|
| MSC2499550A | DRUG | Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period. |
| Cysticide | DRUG | Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period. |
Inclusion Criteria: * Healthy males aged 18-55 years of age (inclusive at screening) * Male subjects with partners of childbearing potential must have had a vasectomy or use acceptable methods of birth control (that is, condoms) and not donate sperm during, and until 90 days after the last dose of ...
MSC2499550A is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development. The only completed trial evaluated its relative bioavailability in healthy male participants. It is not approved for any medical condition and remains under investigation.
MSC2499550A is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this investigational small molecule. As of now, the drug is in Phase 1 development and has not been approved for any use.
MSC2499550A is in Phase 1 clinical development. One Phase 1 trial has been completed, with no active trials currently ongoing. The drug is investigational and has not received FDA approval. It is being studied in healthy volunteers to assess its bioavailability.
MSC2499550A has one completed clinical trial, NCT02271984, titled "Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers." This Phase 1 study enrolled 36 healthy male participants in Germany. The trial was controlled but not double-blinded, and it has been completed.
MSC2499550A is not the same as L-Praziquantel. The completed clinical trial NCT02271984 studied the relative bioavailability of L-Praziquantel, but MSC2499550A is a distinct investigational small molecule. No alternative names for MSC2499550A have been established in the available data.